Tidal Investments LLC Buys 14,947 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tidal Investments LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 265.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,576 shares of the biopharmaceutical company’s stock after acquiring an additional 14,947 shares during the period. Tidal Investments LLC’s holdings in Halozyme Therapeutics were worth $1,178,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Verdence Capital Advisors LLC increased its holdings in Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 261 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Private Advisor Group LLC raised its position in Halozyme Therapeutics by 1.8% in the 2nd quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after buying an additional 412 shares during the last quarter. Finally, Juncture Wealth Strategies LLC lifted its stake in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 415 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock worth $1,621,800 over the last ninety days. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent research reports. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $61.11.

Get Our Latest Stock Report on HALO

Halozyme Therapeutics Stock Up 1.0 %

HALO stock opened at $47.32 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The business’s 50 day simple moving average is $51.03 and its 200 day simple moving average is $54.04. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $6.02 billion, a PE ratio of 15.67, a PEG ratio of 0.43 and a beta of 1.23.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Stories

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.